The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MDS 2021 | Novel strategies for treating cytopenia in MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses novel treatments for cytopenia in myelodysplastic syndromes (MDS) at ESH MDS 2021. In particular, he highlights anti-inflammatory treatments in the early stages of development and a Phase II/III trial (NCT02598661) evaluating imetelstat in patients with low- or intermediate-risk MDS. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
